Glucos Fresenius Kabi (Glucose)

Glucos Fresenius Kabi is indicated for several clinical situations where rapid glucose delivery and fluid support are required.

• Treatment of acute hypoglycemia in hospitalized patients.
• Component of parenteral nutrition regimens for patients unable to eat orally.
• Fluid replacement in patients with dehydration or electrolyte imbalance.
• Support during surgical procedures requiring intravenous glucose.
• Adjunct therapy for patients receiving medications that may lower blood glucose levels.

Glucos Fresenius Kabi may be associated with a range of adverse reactions, most of which are related to the intravenous administration of glucose.

Common

• Mild hyperglycemia or transient rise in blood glucose.
• Local irritation or pain at the infusion site.
• Nausea or mild gastrointestinal discomfort.
• Headache or dizziness during rapid infusion.
• Electrolyte shifts, particularly potassium changes.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Hypersensitivity reactions, including rash or urticaria.
• Fluid overload causing pulmonary edema.
• Hyperosmolar hyperglycemic state in susceptible patients.
• Metabolic acidosis secondary to rapid glucose metabolism.

When using Glucos Fresenius Kabi, clinicians should consider several safety factors to minimize risk.

• Assess baseline blood glucose and monitor levels frequently during infusion.
• Adjust infusion rate in patients with renal or cardiac insufficiency to avoid fluid overload.
• Use caution in patients with known hypersensitivity to glucose solutions or excipients.
• Verify compatibility with other intravenous medications before co‑administration.
• Consider electrolyte status, especially potassium and sodium, before and during therapy.
• Document and report any unexpected adverse reactions promptly.

Glucos Fresenius Kabi can interact with other agents administered intravenously or affect metabolic pathways.

Avoid

• Concurrent infusion of high‑dose insulin without appropriate glucose monitoring.
• Mixing with calcium‑containing solutions that may precipitate.
• Co‑administration with medications that significantly lower blood glucose (e.g., sulfonylureas) without dose adjustment.

Use with caution

• Concurrent use of diuretics that may alter fluid balance.
• Administration alongside beta‑blockers, which can mask hypoglycemia symptoms.
• Co‑infusion with potassium chloride solutions; monitor serum potassium.
• Use in patients receiving total parenteral nutrition containing other carbohydrate sources.
• Combination with vasopressors; monitor hemodynamic response.